- Filter:
- All
- News
- White Papers
- Articles
- Peer-reviewed Work
Evidence for Change: Effectiveness of Behaviour Change Techniques in Medication Adherence Interventions
Thursday, April 4, 2024
Professor John Weinman, our Behavioral Science Lead in Europe, discusses his recent systematic review on commonly reported behavior change techniques in successful medication adherence intervention studies in Type 2 Diabetes.
Case Study: myMeds—A multichannel support program for Type 2 Diabetes
Tuesday, March 26, 2024
Overview of a highly-personalized, multichannel experience for Type 2 Diabetes patients on oral hypoglycemic agents in a tailored 26-week journey.
Digital Technology Uptake in Rare Disease
Friday, February 23, 2024
Explore our report revealing insights about digital technology use in those living with a rare disease and their caregivers.
Evidence for Change: Smartphone App Effectiveness for Healthy Eating Behaviours
Monday, February 12, 2024
A discussion of a recent systematic review on the use of smartphone apps for improving healthy eating behaviors.
Case Study: Patient Support App for people living with type 2 diabetes on a self-injection medication
Monday, February 12, 2024
Applying our behavior change approach and the Atlantis Health Patient Support App, we empower people living with type 2 diabetes to manage their self-injection treatment and the impact of the disease.
Case Study: Highly personalized PSP for people living with multiple myeloma taking a complex oral treatment
Thursday, February 1, 2024
A Patient Support Program that applies our behavior change approach to deliver better treatment adherence and outcomes for people with multiple myeloma.
Co-designing a Patient Support Program for a Multiple Myeloma therapy
Sunday, November 12, 2023
Atlantis Health co-authored a poster presented at the International Myeloma Society Annual Meeting in Athens and at Blood 2023, the Annual Scientific Meeting of the Haematology Society of Australia and New Zealand. We described a co-designed patient support program delivered by Atlantis Health that offered personalized, multichannel support to patients at key time points aligned with their XPO-1 inhibitor treatment for relapsed/refractory multiple myeloma.
Designed in collaboration with Antengene (AUS) Pty Ltd, Myeloma Australia and healthcare professionals, the program complements the care provided by their hospital-based treating team in achieving optimal patient outcomes.
Atlantis Health Awarded Highly Commended for Excellence in Patient Support at the 2023 PRIME Awards
Friday, November 10, 2023
Our Atlantis Health Australia team, in collaboration with Swedish Orphan Biovitrum (Sobi) Australia, have proudly received a Highly Commended award for Excellence in Patient at the 2023 PRIME Awards for the EMPower Support Ecosystem. EMPower is a wrap-around, personalized support service co-designed with and for people living with the ultra-rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH), helping them to initiate treatment and manage the impact of PNH.
"Sobi is delighted to see EMPower being awarded Highly Commended in the category of Excellence in Patient or Customer Support at the PRIME Awards 2023. We’ve partnered with Atlantis Health to understand the needs of the PNH community including HCPs, the patients they treat and their carers, to identify the PNH treatment journey. By embracing Sobi’s core values of care and partnership, we have been able to design and implement an ecosystem of support with the EMPower Program" - Sharon Lo, Patient Services Manager, Swedish Orphan Biovitrum Pty Ltd (Sobi)